Xin Li

Title: Innovations of Xin Li in Anti-HBV Pharmaceutical Development

Introduction

Xin Li is a notable inventor based in Weifang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-HBV (hepatitis B virus) treatments. His innovative work has led to the creation of a unique sulfonamide benzamide derivative that holds promise in combating HBV.

Latest Patents

Xin Li holds a patent for a sulfonamide benzamide derivative and its preparation method and application. This compound, characterized by its structure shown in Formula II, can be synthesized through a series of chemical reactions, including sulfonation, acylation, and sulfonylation. The sulfonamide benzamide derivative has demonstrated effective activity against HBV by inhibiting HBV DNA replication in vitro. He has 1 patent to his name, showcasing his innovative approach to pharmaceutical development.

Career Highlights

Xin Li is affiliated with Weifang Medical University, where he continues to engage in research and development in the pharmaceutical field. His work is pivotal in advancing treatments for viral infections, particularly hepatitis B. His dedication to innovation in medicine is evident through his research and patent contributions.

Collaborations

Xin Li collaborates with esteemed colleagues, including Haiyong Jia and Chuanju Li. These partnerships enhance the research environment and foster the development of new pharmaceutical solutions.

Conclusion

Xin Li's contributions to the field of anti-HBV pharmaceuticals highlight the importance of innovation in medical research. His patented work on sulfonamide benzamide derivatives represents a significant step forward in the fight against hepatitis B.